Literature DB >> 12414070

Longitudinal study of symptoms and cognitive function in chronic schizophrenia.

Catherine Hughes1, Veena Kumari, William Soni, Mrigendra Das, Brendon Binneman, Sonia Drozd, Shaun O'Neil, Vallakalil Mathew, Tonmoy Sharma.   

Abstract

There is conflicting evidence of a relationship between changes in symptoms and cognitive functioning in schizophrenia. This study investigated longitudinal changes in psychopathology and cognitive functioning in chronic schizophrenia utilising three different dimensional models of symptomatology. Sixty-two patients diagnosed with DSM-IV schizophrenia or schizoaffective disorder were examined on two occasions over a period of 6 months for symptom improvement, measured by Positive and Negative Syndrome Scale (PANSS) [Kay et al., Schizophr. Bull. 13 (1987) 261]. Participants also completed a comprehensive battery of neuropsychological tasks designed to assess attention, verbal and non-verbal memory, psychomotor processing and executive/frontal functioning on both occasions. Twenty-five control subjects were assessed for comparison purposes. Severity of negative symptoms predicted poor neuropsychological performance on IQ, verbal fluency and memory measures at occasion one. However, using regression analyses, significant improvements in symptom ratings over time using two-, three- or five-dimensional models did not predict improvements in any aspect of cognitive functioning measured, except motor speed. The results do not suggest a causal relationship between the course of symptoms and neuropsychological functioning in chronic schizophrenia. Copyright 2002 Elsevier Science B.V.

Entities:  

Mesh:

Year:  2003        PMID: 12414070     DOI: 10.1016/s0920-9964(01)00393-0

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  45 in total

Review 1.  Insights and treatment options for psychiatric disorders guided by functional MRI.

Authors:  Tonmoy Sharma
Journal:  J Clin Invest       Date:  2003-07       Impact factor: 14.808

2.  Low BDNF is associated with cognitive impairment in chronic patients with schizophrenia.

Authors:  Xiang Yang Zhang; Jun Liang; Da Chun Chen; Mei Hong Xiu; Fu De Yang; Therese A Kosten; Thomas R Kosten
Journal:  Psychopharmacology (Berl)       Date:  2012-01-26       Impact factor: 4.530

3.  Cognitive predictors of social functioning improvements following cognitive remediation for schizophrenia.

Authors:  Clare Reeder; Nicola Smedley; Kate Butt; Diana Bogner; Til Wykes
Journal:  Schizophr Bull       Date:  2006-08-10       Impact factor: 9.306

4.  Dissociation of acute and chronic intermittent phencyclidine-induced performance deficits in the 5-choice serial reaction time task: influence of clozapine.

Authors:  David M Thomson; Allan McVie; Brian J Morris; Judith A Pratt
Journal:  Psychopharmacology (Berl)       Date:  2010-09-29       Impact factor: 4.530

5.  Premorbid IQ varies across different definitions of schizophrenia.

Authors:  Annick Urfer Parnas; Lennart Jansson; Peter Handest; Jan Nielsen; Ditte Sæbye; Josef Parnas
Journal:  World Psychiatry       Date:  2007-02       Impact factor: 49.548

Review 6.  [Cognitive disorders in schizophrenic patients].

Authors:  H-P Volz; F Reischies; M Riedel
Journal:  Nervenarzt       Date:  2010-01       Impact factor: 1.214

Review 7.  Genetics of clinical features and subtypes of schizophrenia: a review of the recent literature.

Authors:  Ayman H Fanous; Kenneth S Kendler
Journal:  Curr Psychiatry Rep       Date:  2008-04       Impact factor: 5.285

8.  Should cognitive impairment be included in the diagnostic criteria for schizophrenia?

Authors:  Richard S E Keefe
Journal:  World Psychiatry       Date:  2008-02       Impact factor: 49.548

9.  Cognitive effects of olanzapine and clozapine treatment in chronic schizophrenia.

Authors:  Tonmoy Sharma; Catherine Hughes; William Soni; Veena Kumari
Journal:  Psychopharmacology (Berl)       Date:  2003-07-04       Impact factor: 4.530

10.  Relationships among neurocognition, symptoms and functioning in patients with schizophrenia: a path-analytic approach for associations at baseline and following 24 weeks of antipsychotic drug therapy.

Authors:  Ilya A Lipkovich; Walter Deberdt; John G Csernansky; Bernard Sabbe; Richard Se Keefe; Sara Kollack-Walker
Journal:  BMC Psychiatry       Date:  2009-07-14       Impact factor: 3.630

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.